Showing 2221-2230 of 5643 results for "".
- Oculus Announces Parnership with Luvo to Offer New IPL and RF Devices for the US Ophthalmic Markethttps://modernod.com/news/oculus-announces-parnership-with-luvo-to-offer-new-ipl-and-rf-devices-for-the-us-ophthalmic-market/2481853/Oculus has announced a strategic partnership with Luvo to bring new specialty care devices to the US optometry and ophthalmology market. As part of the deal, Oculus is launching the Luvo Lucent and Darwin with Intense Pulse Light and Radio Frequency therapy, which are designed to e
- Otsuka and ShapeTX Collaborate to Develop AAV Gene Therapies for Ocular Diseaseshttps://modernod.com/news/otsuka-and-shapetx-collaborate-to-develop-aav-gene-therapies-for-ocular-diseases/2481832/Otsuka Pharmaceutical and ShapeTX, a programmable medicine company using artificial intelligence (AI) and RNA to combat genetic diseases, announced a multitarget collaboration to develop intravitreally delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional t
- Study Finds Role of Biosynthetic Fatty Acid Pathway Insufficiencies in Age-Related Macular Degenerationhttps://modernod.com/news/study-finds-role-of-biosynthetic-fatty-acid-pathway-insufficiencies-in-age-related-macular-degeneration/2481831/LSU Health Sciences Center announced the publication of findings that suggest that age-related macular degeneration (AMD) decreases an essential fatty acid, preventing the formation of a class of protective molecules and reducing repair potential. The research was led by Nicolas Bazan,
- NovaBay Pharmaceuticals’ Avenova Allograft is Launched in the United Stateshttps://modernod.com/news/novabay-pharmaceuticals-avenova-allograft-is-launched-in-the-united-states/2481830/NovaBay Pharmaceuticals announced the launch of the Avenova Allograft in the United States through its physician-dispensed channel. The company’s prescription optic allograft, which is intended for use as a protective covering during the repair of ocular surfaces, is manufactured using BioS
- Link Biologics and Théa Open Innovation Enter Partnership to Develop Drug Candidate for Dry Eye Diseasehttps://modernod.com/news/link-biologics-and-thea-open-innovation-enter-partnership-to-develop-drug-candidate-for-dry-eye-disease/2481828/Link Biologics Limited and Théa Open Innovation announced that they have entered into an agreement to co-develop Link_TSG6 for the treatment of dry eye disease (DED) and other ophthalmology indications, worldwide excluding Asia. Link_TSG6 is a biological drug based on human TSG-6
- NovaBay Pharmaceuticals Enters Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allografthttps://modernod.com/news/novabay-pharmaceuticals-enters-agreement-with-biostem-technologies-to-commercialize-amniotic-tissue-allograft-as-avenova-allograft/2481821/NovaBay Pharmaceuticals and BioStem Technologies announced an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces. Fi
- Award-Winning Actress, Dancer and Director Debbie Allen Joins Prevent Blindness and Regeneron to Raise Awareness of Serious Retinal Diseaseshttps://modernod.com/news/award-winning-actress-dancer-and-director-debbie-allen-joins-prevent-blindness-and-regeneron-to-raise-awareness-of-serious-retinal-diseases/2481818/Award-winning actress, dancer and director Debbie Allen is partnering with Prevent Blindness and Regeneron to launch the 'Gr8 Eye Movement,' a new disease awareness campaign that aims to address gaps in how people understand the risk of developing certain serious retinal di
- DigitalOptometrics to Demonstrate Its Remote Comprehensive Exam Services With Instant Language Translation Capabilities at Vision Expo Westhttps://modernod.com/news/digitaloptometrics-to-demonstrate-its-remote-comprehensive-exam-services-with-instant-language-translation-capabilities-at-vision-expo-west/2481811/DigitalOptometrics, a provider of remote comprehensive eye exam services, will demonstrate its technology at Vision Expo West, September 28-30. Attendees can interact with a remote optometrist in real-time and experience a patient-centric comprehensive eye exam conducted via high-definition
- Penn Medicine Neuroscientists Identify Brain Mechanism that Drives Focus Despite Distractionshttps://modernod.com/news/penn-medicine-neuroscientists-identify-brain-mechanism-that-drives-focus-despite-distractions/2481770/In a new study published in Neuron, neuroscientists in the Perelman School of Medicine at the University of Pennsylvania sought to illuminate the neural mechanism that helps the brain decide whether to focus visual
- Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302https://modernod.com/news/opthea-announces-sozinibercept-as-the-nonproprietary-drug-name-for-opt-302/2481747/Opthea announced that the American Medical Association’s United States Adopted Names (USAN) Council has approved the nonproprietary drug name “sozinibercept” for the company’s lead biologic drug candidate, OPT-302. Sozinibercept (OPT-302) is